In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

In the latest trading session, Pfizer (PFE) closed at $26.64, marking a +1.29% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.88% for the day. Meanwhile, the ...

Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

After catching up with Pfizer’s Chairman and CEO, CFO, Chief Scientific Officer and Chief Strategy and Innovation Officer at the firm’s healthcare conference, JPMorgan analyst ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xencor (XNCR – Research Report) and Pfizer (PFE – Research ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...